BridgeMD
Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia with open-label Part I and randomized, double-blind, placebo-controlled Part II.
EU CTIS ID: 2024-516852-17-00
What this study is testing
To evaluate efficacy of ADE513 in reducing abnormal involuntary movements of tardive dyskinesia.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subject aged between 18 and 75 years, inclusive.
- Subject in good general health with expectation to attend all study visits and complete all study assessments as judged by the Investigator.
- Subject able to read, comprehend and provide the written informed consent.
- Subject able to complete subject-facing rating scales.
- Female subject of childbearing potential who agrees to use a highly effective form of contraception (as defined by the Protocol) throughout the Study.
- Subject with a clinical diagnosis of tardive dyskinesia.
You likely can't join if
- Subject who received any of the following medications within 30 days of Screening or Baseline: o Tetrabenazine, deutetrabenazine, valbenazine, reserpine, α-methyl-p-tyrosine (AMPT), o Trihexyphenidyl, orphenadrine, procyclidine, biperiden or other strong anticholinergics o Metoclopramide, promethazine, and prochlorperazine o Methylphenidate, amphetamine/dextroamphetamine, or other stimulants, o Monoamine oxidase inhibitors (MAOIs) o Levodopa or dopamine agonists o Botulinum toxin (within 3 months of Screening) Note: Existing medication for the subject’s TD symptoms must not be discontinued solely for the purpose of inclusion in this clinical trial.
- Subject with clinically significant cardiac abnormality or QTcF >450 ms (males) or >470 ms (females) on 12-lead ECG at Screening.
- Subject with any of the following abnormal values in laboratory test results at Screening: o aspartate transaminase (AST) or alanine aminotransferase (ALT) >2.5 times the upper limit of normal (ULN) o alkaline phosphatase (ALP) or total bilirubin >2 times the ULN, o serum creatinine >1.5 times the ULN o any other results outside of laboratory reference ranges judged as clinically significant by the Investigator o positive hepatitis B surface antigen (HbSAg, indicating ongoing hepatitis B infection), or positive human immunodeficiency virus antibody (HIV-Ab) or positive hepatitis C antibodies (HCV) test result.
- Subject with a known allergy or hypersensitivity to any component of ADE513, or to a VMAT2 inhibitor e.g. tetrabenazine, deutetrabenazine, valbenazine.
- Subject who has received any investigational drug product within 30 days (or 5 drug half-lives, if longer than 30 days) of Screening.
- Subject acknowledging present alcohol or substance abuse at Screening, or subject with a history thereof within 12 months of Screening, or subject expected to be unable to refrain from substance abuse during the study.
See the full eligibility criteria
Who can join
- Subject aged between 18 and 75 years, inclusive.
- Subject in good general health with expectation to attend all study visits and complete all study assessments as judged by the Investigator.
- Subject able to read, comprehend and provide the written informed consent.
- Subject able to complete subject-facing rating scales.
- Female subject of childbearing potential who agrees to use a highly effective form of contraception (as defined by the Protocol) throughout the Study.
- Subject with a clinical diagnosis of tardive dyskinesia.
- Subject with symptoms of TD which are bothersome and/or cause functional impairment.
- Subject with total motor AIMS score of ≥6, and with abnormal movements judged as moderate or severe by the Investigator (based on Item 8 of the AIMS).
- Subject with body weight of not less than 45kg for females and 55kg for males.
- Subject in a psychiatrically stable condition with no change in psychoactive medications (eg. Neuroleptics, benzodiazepines, anticonvulsants, mood stabilizers etc.) within the last 30 days before Screening, and with no anticipated changes to the subject’s treatment regimen in the next 3 months.
- Subject living in a stable environment as judged by the Investigator, with adequate supervision when necessary.
- Subject having a caregiver who is in regular personal contact with the subject (no less than 5 days a week); if locally required.
- Subject compliant with prescribed treatment regimen as judged by the Investigator.
What rules you out
- Subject who received any of the following medications within 30 days of Screening or Baseline: o Tetrabenazine, deutetrabenazine, valbenazine, reserpine, α-methyl-p-tyrosine (AMPT), o Trihexyphenidyl, orphenadrine, procyclidine, biperiden or other strong anticholinergics o Metoclopramide, promethazine, and prochlorperazine o Methylphenidate, amphetamine/dextroamphetamine, or other stimulants, o Monoamine oxidase inhibitors (MAOIs) o Levodopa or dopamine agonists o Botulinum toxin (within 3 months of Screening) Note: Existing medication for the subject’s TD symptoms must not be discontinued solely for the purpose of inclusion in this clinical trial.
- Subject with clinically significant cardiac abnormality or QTcF >450 ms (males) or >470 ms (females) on 12-lead ECG at Screening.
- Subject with any of the following abnormal values in laboratory test results at Screening: o aspartate transaminase (AST) or alanine aminotransferase (ALT) >2.5 times the upper limit of normal (ULN) o alkaline phosphatase (ALP) or total bilirubin >2 times the ULN, o serum creatinine >1.5 times the ULN o any other results outside of laboratory reference ranges judged as clinically significant by the Investigator o positive hepatitis B surface antigen (HbSAg, indicating ongoing hepatitis B infection), or positive human immunodeficiency virus antibody (HIV-Ab) or positive hepatitis C antibodies (HCV) test result.
- Subject with a known allergy or hypersensitivity to any component of ADE513, or to a VMAT2 inhibitor e.g. tetrabenazine, deutetrabenazine, valbenazine.
- Subject who has received any investigational drug product within 30 days (or 5 drug half-lives, if longer than 30 days) of Screening.
- Subject acknowledging present alcohol or substance abuse at Screening, or subject with a history thereof within 12 months of Screening, or subject expected to be unable to refrain from substance abuse during the study.
- Subject with a positive urine drug screen at Screening.
- Pregnant or breastfeeding subject.
- Applicable only to investigator sites in Slovakia: Subject with presence of parkinsonism, pheochromocytoma and prolactin dependent tumours, e.g. pituitary or breast cancer.
- Subject with a neurological condition that may interfere with the assessment of dyskinesia severity.
- Subject with a serious psychiatric condition that is untreated or undertreated at Screening and/or Baseline.
- Subject with active suicidal ideation at Screening or Baseline.
- Subject with history of either previous intent to act on a suicidal ideation with a specific plan, or previous preparatory acts to commit suicide or suicidal behaviour, or a previous actual, interrupted or aborted suicide attempt.
- Subject with an abnormal score on the depression subscale of the Hospital Anxiety and Depression Scale (HADS) at Screening or Baseline. Abnormal score is defined as score ≥11.
- Subject with an unstable or serious medical condition at Screening or Baseline.
- Subject with developmental disability or evidence of dementia confirmed by Mini-Mental State Exam (MMSE score ≤24).
- Subject showing violent behaviour, or subject with a history thereof within 3 months of start of study participation.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.